Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma Segment includes all ...

In January 2024, Gotham, which had previously shorted Grifols shares, released a report accusing the company of overstating ...

Grifols, a company that turns blood plasma into therapies for immunological disorders and other conditions, is laying off about 2,000 U.S. workers as part of a corporate restructuring projected to ...